Anika Therapeutics, Inc. (ANIK) Gross Margin
- Gross margin · 12 months: Value 62.16%; Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | 62.16% | Gross profit / revenue. Period ending 2026-06-30. $75.00M ÷ $120.65M × 100 ≈ 62.16% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | 75.00M USD | Gross Profit |
| Revenue | 120.65M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 45.65M USD | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | $75.00M | $120.65M | $45.65M | 62.16% |
| 2026-03-31 | $68.12M | $116.26M | $48.14M | 58.59% |
| 2025-12-31 | $63.81M | $112.82M | $49.01M | 56.56% |
| 2025-09-30 | $61.75M | $112.81M | $51.05M | 54.74% |
| 2025-06-30 | $65.58M | $114.55M | $48.97M | 57.25% |
| 2025-03-31 | $71.70M | $117.05M | $45.35M | 61.26% |
| 2024-12-31 | $76.00M | $119.91M | $43.91M | 63.38% |
| 2024-09-30 | $79.76M | $164.17M | $84.41M | 48.59% |
| 2024-06-30 | $103.27M | $166.88M | $63.61M | 61.88% |
| 2024-03-31 | $104.87M | $169.26M | $64.39M | 61.96% |
| 2023-12-31 | $103.09M | $166.66M | $63.57M | 61.85% |
| 2023-09-30 | $100.89M | $163.31M | $62.42M | 61.78% |
| 2023-06-30 | $98.72M | $162.11M | $63.39M | 60.90% |
| 2023-03-31 | $94.61M | $157.47M | $62.85M | 60.09% |
| 2022-12-31 | $93.58M | $156.24M | $62.66M | 59.89% |
| 2022-09-30 | $87.58M | $152.44M | $64.86M | 57.45% |
| 2022-06-30 | $87.82M | $151.71M | $63.88M | 57.89% |
| 2022-03-31 | $83.77M | $150.19M | $66.42M | 55.78% |
| 2021-12-31 | $82.94M | $147.79M | $64.85M | 56.12% |
| 2021-09-30 | $81.55M | $144.66M | $63.11M | 56.38% |
| 2021-06-30 | $75.87M | $136.82M | $60.95M | 55.46% |
| 2021-03-31 | $68.80M | $129.35M | $60.55M | 53.19% |
| 2020-12-31 | $69.03M | $130.46M | $61.43M | 52.91% |
| 2020-09-30 | (m) | $127.54M | $54.14M | (m) |
| 2020-06-30 | (m) | $125.54M | $45.74M | (m) |
| 2020-03-31 | (m) | $125.28M | $35.64M | (m) |
| 2019-12-31 | $85.77M | $114.61M | $28.75M | 74.83% |
| 2019-09-30 | (m) | $111.79M | $27.10M | (m) |
| 2019-06-30 | (m) | $108.88M | $29.43M | (m) |
| 2019-03-31 | (m) | $109.01M | $30.75M | (m) |
| 2018-12-31 | $74.25M | $105.56M | $31.28M | 70.34% |
| 2018-09-30 | $74.47M | $107.99M | $32.99M | 68.96% |
| 2018-06-30 | $76.90M | $108.38M | $30.96M | 70.95% |
| 2018-03-31 | $76.53M | $111.30M | $29.13M | 68.76% |
| 2017-12-31 | $80.42M | $113.42M | (m) | 70.90% |
| 2017-09-30 | (m) | $112.76M | (m) | (m) |
| 2017-06-30 | (m) | $111.36M | (m) | (m) |
| 2017-03-31 | (m) | $104.48M | (m) | (m) |
| 2016-12-31 | $78.91M | $103.38M | (m) | 76.33% |
| 2016-09-30 | (m) | $105.55M | (m) | (m) |
| 2016-06-30 | (m) | $103.44M | (m) | (m) |
| 2016-03-31 | (m) | $99.76M | (m) | (m) |
| 2015-12-31 | $66.64M | $93.00M | (m) | 71.66% |
| 2015-09-30 | (m) | $85.36M | (m) | (m) |
| 2015-06-30 | (m) | $83.73M | (m) | (m) |
| 2015-03-31 | (m) | $87.10M | (m) | (m) |
| 2014-12-31 | $54.54M | $105.59M | (m) | 51.65% |
| 2014-09-30 | (m) | $103.59M | (m) | (m) |
| 2014-06-30 | (m) | $99.29M | (m) | (m) |
| 2014-03-31 | (m) | $93.84M | (m) | (m) |
| 2013-12-31 | $49.01M | $75.08M | (m) | 65.27% |
| 2013-09-30 | (m) | $76.44M | (m) | (m) |
| 2013-06-30 | (m) | $73.45M | (m) | (m) |
| 2013-03-31 | (m) | $72.24M | (m) | (m) |
| 2012-12-31 | $39.02M | $71.36M | (m) | 54.68% |
| 2012-09-30 | (m) | $67.20M | (m) | (m) |
| 2012-06-30 | (m) | $70.89M | (m) | (m) |
| 2012-03-31 | (m) | $67.40M | (m) | (m) |
| 2011-12-31 | (m) | $64.78M | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | $55.56M | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | $40.14M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |